Novo Nordisk, the marketing authorisation holder for Ozempic, has notified the HPRA of intermittent supply issues with Ozempic products due to increased global demand. The company anticipates that intermittent supply will continue throughout 2023.
Novo Nordisk has implemented monthly allocations to help ensure continuity of supply and equitable distribution of Ozempic stock to Irish patients.
The company has issued letters to relevant stakeholders, including healthcare professionals to ensure they are aware of this supply issue and its management.
According to Novo Nordisk, production issues in August at a manufacturing site will lead to a reduction in the overall supply of the 1mg strength of Ozempic to Ireland and other EU markets during the month of September. A potential further brief (approximately one week) constraint of the 0.5mg strength is anticipated in early October.
Novo Nordisk has confirmed that these production issues are now resolved. It is expected that supply of the 1mg strength to Ireland will return to standard 2023 levels from October.